alendronate has been researched along with abaloparatide in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 7 (58.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bilezikian, JP; Black, D; Christiansen, C; Cosman, F; Fitzpatrick, LA; Hattersley, G; Hu, MY; Miller, PD; Riis, BJ; Valter, I; Williams, GC | 1 |
| Al Daghri, N; Bruyère, O; Kaufman, JM; Reginster, JY | 1 |
| Bilezikian, JP; Bone, HG; Cosman, F; Dore, RK; Fitzpatrick, LA; Hattersley, G; Hu, MY; Miller, PD; Mitlak, B; Papapoulos, S; Rizzoli, R; Saag, KG; Williams, GC | 1 |
| Becker, R; Hay, JW; Le, QA; Wang, Y | 1 |
| Dore, RK; Hattersley, G; Hu, MY; Lane, NE; Leder, BZ; Singer, AJ; Zapalowski, C | 1 |
| Bockman, RS; Hattersley, G; Hu, MY; Leder, BZ; Mitlak, B | 1 |
| Bilezikian, JP; Cipriani, C | 1 |
| Batur, P; Tough DeSapri, K | 1 |
| Fitzpatrick, LA; Hiligsmann, M; Reginster, JY; Silverman, SS; Weiss, R; Williams, SA | 1 |
| Cosman, F; Deal, C; Fitzpatrick, LA; Greenspan, SL; Harvey, NC; McClung, M; Mitlak, B; Wang, Y | 1 |
| Bilezikian, JP; Bone, HG; Cosman, F; Fitzpatrick, LA; McCloskey, EV; Miller, PD; Mitlak, B | 1 |
| Caminis, J; Hiligsmann, M; Mathew, J; Pearman, L; Reginster, JY; Silverman, SS; Singer, AJ; Wang, Y | 1 |
1 review(s) available for alendronate and abaloparatide
| Article | Year |
|---|---|
Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Humans; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Postmenopause; Risk Factors | 2020 |
5 trial(s) available for alendronate and abaloparatide
| Article | Year |
|---|---|
Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Female; Humans; Injections, Subcutaneous; Kaplan-Meier Estimate; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Proportional Hazards Models; Spinal Fractures | 2017 |
Effect of a sequential treatment combining abaloparatide and alendronate for the management of postmenopausal osteoporosis.
Topics: Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Bone; Humans; Injections, Subcutaneous; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Peptide Fragments; Placebo Effect; Procollagen | 2018 |
ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Substitution; Female; Femur Neck; Humans; Maintenance Chemotherapy; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Placebos; Spinal Fractures | 2018 |
Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial.
Topics: Aged; Alendronate; Bone Density; Humans; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Risk Factors; Risk Reduction Behavior | 2019 |
Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Drug Therapy, Combination; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Placebos; Radiography; Risk Factors; Spinal Fractures; Treatment Outcome | 2020 |
6 other study(ies) available for alendronate and abaloparatide
| Article | Year |
|---|---|
Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Costs; Female; Fractures, Bone; Health Care Costs; Humans; Middle Aged; Models, Economic; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein; Quality-Adjusted Life Years; Teriparatide; Treatment Outcome; United States | 2019 |
Osteoanabolics Versus Antiresorptives: Which First?
Topics: Alendronate; Female; Humans; Osteoporosis; Parathyroid Hormone-Related Protein; Postmenopause; Risk Reduction Behavior | 2020 |
Osteoporosis Management.
Topics: Alendronate; Anorexia Nervosa; Bone and Bones; Bone Density Conservation Agents; Contraceptives, Oral; Disease Management; Humans; Osteoporosis; Parathyroid Hormone-Related Protein | 2020 |
Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy in women at increased risk of fracture: A US payer perspective.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Middle Aged; Osteoporotic Fractures; Parathyroid Hormone-Related Protein; Quality-Adjusted Life Years | 2020 |
Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend.
Topics: Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone-Related Protein | 2020 |
Cost-Effectiveness of Sequential Abaloparatide/Alendronate in Men at High Risk of Fractures in the United States.
Topics: Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality-Adjusted Life Years; Teriparatide; United States | 2023 |